Released on = February 1, 2007, 11:24 pm

Press Release Author = Aurigene Discovery Technologies Limited and Forest
Laboratories, Inc.

Industry = Biotech

Press Release Summary = Aurigene Discovery Technologies, Ltd (Aurigene), a
Bangalore-based discovery services company and Forest Laboratories Holdings, Ltd.,
a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX) announced today
that the two companies have entered into a collaboration agreement to discover small
molecule drug candidates for a novel obesity and metabolic disorders target

Press Release Body = BANGALORE, India and NEW YORK, January 30, 2007-- Aurigene
Discovery Technologies, Ltd (Aurigene), a Bangalore-based discovery services company
and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest
Laboratories, Inc. (NYSE: FRX) announced today that the two companies have entered
into a collaboration agreement to discover small molecule drug candidates for a
novel obesity and metabolic disorders target. Forest selected the target and will
direct the discovery collaboration.
Under the terms of the agreement, Aurigene will undertake and fund discovery and
optimization of lead compounds, with close participation by Forest's scientists.
Forest will have responsibility for and will fund all subsequent drug development
and commercialization activities. In addition, Forest has full ownership of the
compounds developed under the collaboration with unencumbered worldwide rights.
Forest will pay Aurigene undisclosed research milestones according to a pre-defined
research plan, as well as sales milestones upon commercialization of compounds
arising from the collaboration. Aurigene could receive over $60 million in
development and sales milestone payments if a compound is successfully
commercialized.
"Aurigene has been rapidly developing its small molecule discovery capabilities
through a number of ongoing programs at various stages of development," said CSN
Murthy, CEO of Aurigene. "We are excited to leverage Forest's world class
development capabilities and marketing expertise. We believe that our collaboration
can flourish by bringing together the complimentary strengths from both
organizations. This agreement further strengthens Aurigene's unique risk sharing
model of drug discovery partnerships. We are happy to have the opportunity to work
together with Forest."

Dr. Ivan Gergel, Senior Vice President of Scientific Affairs and President of the
Forest Research Institute, commented: \"We look forward to working with Aurigene to
discover novel drug candidates for the treatment of obesity and metabolic disorders.
These conditions have significant unmet medical needs and we believe the target we
have identified holds promise. Our collaboration with Aurigene is an example of the
continued evolution of Forest's business model such that we are now establishing
discovery research partnerships to identify innovative compounds and to secure
worldwide rights to the resulting products. Our search for capable partners led us
to work with Aurigene and we are looking forward to a productive relationship.\"

About Aurigene:
Aurigene Discovery Technologies Limited is a Bangalore-based discovery services
company focused on collaborative drug discovery with pharmaceutical and biotech
companies on a risk-sharing basis. Aurigene has integrated discovery capabilities,
from target to pre-clinical lead optimization, including in vitro and in vivo
biology and medicinal chemistry expertise. Aurigene also has structural biology and
fragment based drug design capabilities, with in-house crystallization (XRD) and Bio
NMR (600 MHz) facilities. The company is engaged in a number of discovery
collaborations and provides discovery chemistry and biology services to companies in
the US and Europe.

About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com ) is a US-based pharmaceutical company
dedicated to identifying, developing, and delivering products that make a positive
difference in peoples\' lives. Forest Laboratories\' growing product line includes
Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and
maintenance treatment of major depressive disorder and for generalized anxiety
disorder; Namenda(R) (memantine HCl), an N-methyl- D-aspartate (NMDA)-receptor
antagonist indicated for the treatment of moderate to severe Alzheimer\'s disease;
Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar*
HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker
and diuretic combination product, each indicated for the treatment of hypertension;
and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial
support for the maintenance of abstinence from alcohol in patients with alcohol
dependence who are abstinent at treatment initiation.
*Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral is a
registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt,
Germany.


Except for the historical information contained herein, this release contains
\"forward-looking statements\" within the meaning of the Private Securities Reform Act
of 1995. These statements involve a number of risks and uncertainties, including the
difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, the timely development and
launch of new products and the risk factors listed from time to time in the
Company's SEC reports, including the Annual Report on Form 10-K for the fiscal year
ended March 31, 2006 and on Form 10-Q for the periods ended June 30, 2006 and
September 30, 2006.


Web Site = http://www.aurigene.com

Contact Details = CSN Murthy
CEO
Aurigene Discovery Technologies Limited,
39-40, KIADB Industrial Area,
Electronic City Phase II, Hosur Road,
Bangalore 560 100,
India

Tel: + 91 80 2852 1314, 2852 1316, 2852 8943
Fax:+ 91 80 2852 6285

murthy_csn@aurigene. com